Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I suspect the veracity of this narrative is on par with your idea that LL was a whistleblower to the FDA, yet went on to author the JAMA-O article. :)
you asked for him to name someone, he did. April might be a great chance to brush up on basic google processes and basic DD. :)
haha nice capitulation. :)
that was easy. :)
https://www.simmons-simmons.com/en/publications/ck0ap5rny6w050b94dcwvj3g2/14-prison-sentence-for-spoofing-highlights-trading-risks
April could be a great time for DD on such basics. :)
More DD would certainly lead you to understand the differences between FDA and MHRA, as well as acceptance vs. approval. April seems like a great opportunity to brush up on these extremely basic points. :)
I see that you also don't understand the difference between acceptance of the application, and approval. April may be a good time to brush up on such basics. :)
to be clear, the MAA is for the UK/ MHRA approval process. Don't want anyone confusing it with the FDA or BLA process. :)
that date format has proven too confusing for some to discern- use caution. :)
called a "CIA guru" by whom?
where are you seeing "pumping"? TIA
A month should be sufficient time to familiarize oneself with the different application processes for different jurisdictions. Then a restoration of credibility on these topics may be attempted (but isn't guaranteed). :)
:) BLA is for the US FDA. This discussion is about MAA application and disclosure thereof. :)
Credibility, you were saying? :)
false- I asked who said it so I could see the context. :)
Please don't put words in my mouth, especially as a moderator. :)
The word is "sequitur". :)
indeed- I just don't recall anything about "immediately" after MIA. That's why I asked. :)
non sequitur, but ok. :)
which board prognosticators said immediately after MIA? TIA.
$15 is an approximate 23-bagger from here- not sure why some people are complaining! :)
this is directly at odds with a statement you made earlier today- very strange. :)
Also, since your PT is $15, I would expect you to be excited to have so many shares to purchase around $0.64. :)
Again, I'm doubtful of your claim that no spoofing occurs/ has occurred on this security. :)
I'm surprised you maintain a $15 price target in light of these thoughts. :)
no spoofing? Interesting that the experts disagree with this claim. :)
LC2020, I always assumed the reason was that people were too interested in the preclinical mouse studies and phase 1 safety trials that you (for some reason) like to post here. :)
It wouldn't make a difference. He knows it isn't true already.
I suspect the veracity of this narrative is on par with your idea that LL was a whistleblower to the FDA and yet proceeded to author the JAMA-O article on the same trial. :)
directly refuted by LL in last Q&A. :)
This welshing is reminiscent of fabricated Checkmate data, and false quotes from the ASM. :)
I suspect this narrative as likely to be true as your idea that Linda Liau was a whistleblower to the FDA, yet then served as first author on the JAMA article. :)
false- the SP isn't 0.63 cents. I find misrepresenting the share price by 100 fold to be a BS narrative. :)
probably true. I look forward to seeing this repeated a few times per day for the next few weeks/ months.
I disagree that shareholder will be diluted under a dollar after approvals. :)
agreed- but the bears have almost run out of space to kick the can much further! :)
I'm :
1) not Hoff
2) not asking about a stock
I'm asking which therapy you are discussing and repeatedly bringing up on this forum. :) Mentioning it and predicting approval without data seems a bit fud fable-ish. :)
Glad to see you again- which personalized immunotherapy that works along with ICIs were you predicting will get US approval this year?
"it’s reasonable to assume that they will need 5X more staff on the manufacturing tech side to get to 100 patient per month volume."
how are you deriving this estimate?
I'm asking you- because you made a statement of fact about efficacy in low grade glioma. :) Guess you don't have the data to show. :)
I'll never understand why easily disprovable premises/ statements are so favored by some. :)
False. Many trials take longer than 16 years, so your statement is untruthful. :)
Q1) A
Q2) B
:)
correct, I missed that. Since advent used DCVAX as the use-case to demonstrate manufacturing capability for cellular product, the MIA can be seen as a completed module for NWBO's application. The PIP submission and approval was too, in a way.